Sphera Funds Management LTD. lifted its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 53.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 116,517 shares of the biotechnology company’s stock after purchasing an additional 40,401 shares during the quarter. Sarepta Therapeutics comprises 1.4% of Sphera Funds Management LTD.’s investment portfolio, making the stock its 16th biggest holding. Sphera Funds Management LTD.’s holdings in Sarepta Therapeutics were worth $12,716,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also bought and sold shares of the company. Delek Group Ltd. acquired a new position in Sarepta Therapeutics in the fourth quarter valued at $3,457,000. Polar Capital LLP grew its position in Sarepta Therapeutics by 301.0% during the fourth quarter. Polar Capital LLP now owns 200,482 shares of the biotechnology company’s stock valued at $21,879,000 after acquiring an additional 150,482 shares during the period. Casdin Capital LLC grew its position in Sarepta Therapeutics by 275.0% during the fourth quarter. Casdin Capital LLC now owns 150,000 shares of the biotechnology company’s stock valued at $16,370,000 after acquiring an additional 110,000 shares during the period. American International Group Inc. grew its position in Sarepta Therapeutics by 7.3% during the fourth quarter. American International Group Inc. now owns 1,605 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 109 shares during the period. Finally, Geode Capital Management LLC grew its position in Sarepta Therapeutics by 11.4% during the fourth quarter. Geode Capital Management LLC now owns 658,753 shares of the biotechnology company’s stock valued at $71,889,000 after acquiring an additional 67,601 shares during the period.
A number of equities research analysts have issued reports on the company. BTIG Research set a $190.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, December 28th. Svb Leerink reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Tuesday, March 5th. Janney Montgomery Scott set a $200.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, January 8th. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Finally, HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 10th. Four investment analysts have rated the stock with a hold rating, twenty-five have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $185.55.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.23. The firm had revenue of $84.40 million during the quarter, compared to analyst estimates of $84.83 million. Sarepta Therapeutics had a negative return on equity of 36.73% and a negative net margin of 120.22%. The firm’s quarterly revenue was up 47.3% on a year-over-year basis. During the same period last year, the company posted ($0.37) EPS. On average, equities analysts anticipate that Sarepta Therapeutics Inc will post -5.17 EPS for the current fiscal year.
In other news, SVP David T. Howton sold 30,000 shares of the firm’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the senior vice president now directly owns 31,196 shares of the company’s stock, valued at approximately $4,367,440. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Sandesh Mahatme sold 65,000 shares of the firm’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $130.23, for a total value of $8,464,950.00. Following the sale, the chief financial officer now directly owns 14,118 shares of the company’s stock, valued at $1,838,587.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 160,000 shares of company stock valued at $22,089,950. 7.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Sphera Funds Management LTD. Has $12.72 Million Position in Sarepta Therapeutics Inc (SRPT)” was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.themarketsdaily.com/2019/03/14/sphera-funds-management-ltd-has-12-72-million-position-in-sarepta-therapeutics-inc-srpt.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Story: New Google Finance Tool and Screening Stocks
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.